Beyond its current late-stage trial, iOnctura's key ambition is to use its well-tolerated oral drug in the adjuvant setting. The goal is to prevent metastasis in the 50% of patients who relapse after primary eye treatment, fundamentally changing their prognosis rather than just managing late-stage disease.

A common theme across the four FDA-approved agents for steroid-refractory chronic GVHD (ibrutinib, belumosudil, ruxolitinib, axatilimab) is a high overall response rate driven primarily by partial remissions. The low rate of complete responses (CRs) highlights a significant unmet need and an opportunity for combination therapies or novel mechanisms.

In a pivotal neoadjuvant trial of cemiplimab for CSCC, none of the 40 patients who achieved a pathologic complete response (path CR) had relapsed at long-term follow-up. This suggests that path CR can be used as a powerful early indicator of long-term disease control and potential cure.

Beyond low mutational burden, uveal melanoma's tendency to metastasize to the liver is a key reason for immunotherapy failure. The liver's microenvironment fosters systemic immune tolerance, creating a major hurdle for checkpoint inhibitors that are effective in other melanomas.

Immunotherapy is now inducing complete responses in a small subset of advanced HCC patients. This success presents a novel challenge, as there is no data to guide decisions on treatment duration, forcing difficult discussions about stopping therapy in patients who may be cured.

In rare NRG1-fusion positive cancers, targeted therapy shows a modest 29% objective response rate, below the typical 40% benchmark for accelerated approval. However, the median duration of response is nearly a year (and 1.5 years in naive patients), making it a highly effective, life-altering therapy for responders. This highlights duration, not just rate, as a key efficacy metric.

With several viable treatment options available, practical considerations are becoming as important as clinical data. A patient's ability to travel, manage weekly infusions, or handle side effects of oral medication are now critical factors in shared decision-making for personalized treatment plans.

The emergence of multiple effective but distinct therapies (systemic, liver-directed, immunotherapy) has created a new clinical challenge. Without head-to-head trials, oncologists must now strategize the optimal sequence and combination for each patient, moving beyond a one-size-fits-all approach.

The durable, long-term survival seen in about 12-13% of extensive-stage SCLC patients treated with immunotherapy is changing the therapeutic mindset. This "tail on the curve" represents a real-world cohort of long-term survivors, pushing clinicians to think beyond pure palliation and toward an attempt at cure for a subset of patients.